Q-omics provides the consensus-scored DOCK4 profile across patient tissues and cancer cell-line models. DOCK4 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, DOCK4 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, DOCK4 RNA expression shows 19,697 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRC as cancer lineages where DOCK4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DOCK4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DOCK4 survival associations across molecular data types. DOCK4 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (12) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DOCK4 RNA expression–survival associations across cancer types. High DOCK4 expression shows unfavorable associations in UVM, KICH and STAD, but favorable associations in KIRC, HNSC and MESO. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for DOCK4 RNA expression.
This table summarizes DOCK4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DOCK4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DOCK4 shows lower tumor expression in LUSC, LUAD and UCEC and higher tumor expression in KIRC, HNSC and KIRP. The KIRC box plot shows higher DOCK4 RNA expression in tumor versus normal tissue (log2 FC = +1.125, t-test p < 0.001).
This table shows molecular features associated with DOCK4 in patient tissues and cancer cell lines. In patient samples, DOCK4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, DOCK4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Lymphoma.
